Source comparison
Best BPC-157 Dosage Post-Surgery Recovery 2026: Protocol Comparison
| Protocol Type | Dosage | Frequency | Duration | Injection Site | Best For | Professional Assessment ||—|—|—|—|—|—|| Standard Research Protocol | 250 mcg | Twice daily (morning/evening) | 4–6 weeks | Subcutaneous, within 2 inches of surgical site | Tendon rep
This comparison does not assign a generated winner or score.
- | Protocol Type | Dosage | Frequency | Duration | Injection Site | Best For | Professional Assessment ||—|—|—|—|—|—|| Standard Research Protocol | 250 mcg | Twice daily (morning/evening) | 4–6 weeks | Subcutaneous, within 2 inches of surgical site | Tendon repairs, ligament reconstruction, fascial closure | Most supported by extrapolated animal data. Dosing reflects human equivalent scaling with bioavailability adjustment || High-Dose Accelerated Protocol | 500 mcg | Twice daily | 6–8 weeks | Subcutaneous peri-site | Complex multi-tissue surgeries, compromised healing (diabetic patients, smokers) | Higher cost with unclear added benefit. Animal studies show dose-response plateau above human equivalent of 350 mcg || Conservative Maintenance Protocol | 250 mcg | Once daily (evening) | 8–12 weeks | Subcutaneous peri-site | Chronic tendinopathy management post-surgery, elderly patients | Extends exposure window but halves daily tissue concentration. May reduce acute healing acceleration ||